Taylor Frigon Capital Management LLC Has $4.20 Million Stock Position in ClearPoint Neuro, Inc. (NASDAQ:CLPT)

Taylor Frigon Capital Management LLC lessened its position in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 11.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 374,797 shares of the company's stock after selling 49,738 shares during the period. ClearPoint Neuro accounts for about 2.1% of Taylor Frigon Capital Management LLC's portfolio, making the stock its 5th biggest holding. Taylor Frigon Capital Management LLC owned about 1.37% of ClearPoint Neuro worth $4,201,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Point72 DIFC Ltd bought a new position in ClearPoint Neuro in the 2nd quarter valued at approximately $32,000. XTX Topco Ltd increased its position in ClearPoint Neuro by 11.6% in the 2nd quarter. XTX Topco Ltd now owns 13,010 shares of the company's stock valued at $70,000 after acquiring an additional 1,353 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of ClearPoint Neuro by 7.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 24,867 shares of the company's stock valued at $170,000 after acquiring an additional 1,813 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of ClearPoint Neuro during the second quarter worth $175,000. Finally, Rinkey Investments bought a new stake in shares of ClearPoint Neuro in the second quarter worth $307,000. 30.08% of the stock is owned by institutional investors and hedge funds.

ClearPoint Neuro Trading Up 2.4 %

CLPT stock traded up $0.29 during midday trading on Thursday, hitting $12.58. The stock had a trading volume of 129,271 shares, compared to its average volume of 183,087. The firm has a market cap of $344.94 million, a P/E ratio of -15.14 and a beta of 1.10. The business has a fifty day moving average price of $11.91 and a two-hundred day moving average price of $8.22. ClearPoint Neuro, Inc. has a 1-year low of $4.05 and a 1-year high of $14.13.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.03. The company had revenue of $7.86 million for the quarter, compared to the consensus estimate of $7.50 million. ClearPoint Neuro had a negative return on equity of 64.23% and a negative net margin of 64.06%. During the same period in the previous year, the business earned ($0.29) EPS. On average, equities analysts anticipate that ClearPoint Neuro, Inc. will post -0.65 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have commented on CLPT shares. B. Riley assumed coverage on ClearPoint Neuro in a report on Thursday, July 25th. They set a "buy" rating and a $10.00 target price on the stock. Lake Street Capital lifted their price objective on ClearPoint Neuro from $11.00 to $15.00 and gave the stock a "buy" rating in a research note on Tuesday, August 27th.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.